Orodispersible Tablets Market Size, Share & Trends Analysis Report by Drug Class (Analgesics, Antiemetics, Antipsychotics, Anti-inflammatory Drugs, Sedatives/Hypnotics, Antihypertensives, Others), By Disease Indication (Central Nervous System Disorders, Gastrointestinal Disorders, Cardiovascular Disorders, Respiratory Disorders, Allergy and Asthma, Others), By Distribution Channel, By Age Group, By End User, By Technology , Region And Segment Forecasts, 2023-2031

Orodispersible Tablets Market Size is valued at 10.71 billion in 2024 and is predicted to reach 29.47 billion by the year 2034 at a 10.8% CAGR during the forecast period for 2025-2034.

The orodispersible tablets market, known as orally disintegrating tablets (ODTs), has acquired substantial interest and appeal in the pharmaceutical sector. These tablets are designed to dissolve fast in the mouth without needing water or swallowing, making them an appealing option for patients who struggle to swallow regular tablets or capsules. Because it includes mostly medical compounds in solid dosage form, orodispersible pills break down quickly, usually in seconds, when placed on the tongue. Because it directly solves pharmaceutical and patient demands, this novel ODT technology improves the patient life cycle.

It creates a comfortable dosage strategy for pediatric, geriatric, and psychiatric patients with dysphagia. This new technology motivates the academic industry to produce a newer orally disintegrating formulation and technology, as well as an evaluation approach suited for drug candidates in the future.

However, Creating an orodispersible tablet formulation with adequate flavor, stability, and disintegration qualities can be difficult. The formulation must protect the tablet during manufacture, packaging, and storage while allowing rapid breakdown in the oral cavity. 

Competitive Landscape:

Global orodispersible tablets market players are:

• AstraZeneca PLC
• GlaxoSmithKline PLC
• Novartis International AG
• Johnson & Johnson Services
• Teva Pharmaceutical Industries Ltd
• Merck & Co., Inc
• Pfizer Inc
• Cipla Limited
• Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd
• Lupin Pharmaceuticals, Inc
• Torrent Pharmaceuticals Ltd
• Hoffmann-La Roche Ltd
• Eisai Co., Ltd
• Takeda Pharmaceutical Company Limited 

Market Segmentation:

The Orodispersible Tablets market is segmented based on drug class, disease indication, distribution channel, age group, and technology. The market is divided into analgesics, antiemetics, antipsychotics, anti-inflammatory drugs, sedatives/hypnotics, and antihypertensives. Based on the disease indication is divided into disorders, respiratory disorders, allergies and asthma, among others.

The market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. Furthermore, it is divided based on age groups into pediatric, adult, and geriatric patients. End users, including hospitals, clinics, ambulatory surgical centers, and home care settings, also categorize the market. Additionally, the market is segmented by technology into lyophilization, tablet molding, spray drying, sublimation, and other methods.

Based On Drug Class, The Anti-Inflammatory Drugs Segment Is A Major Contributor To The Orodispersible Tablets Market

The anti-inflammatory category will hold a major share of the global Orodispersible Tablets market 2022. Increasing research spending in biologics for treating autoimmune inflammatory illnesses has resulted in potential pipeline medications. The benefits of monoclonal antibodies' anti-inflammatory characteristics have turned the emphasis of pharmaceutical behemoths to this field. The firms are developing anti-tumor necrosis factor (TNF) inhibitors, interleukins, and other agents to treat various inflammatory illnesses. 

The Respiratory Disorders Segment Witnessed Growth At A Rapid Rate

The respiratory disorders segment is projected to grow rapidly in the global Orodispersible Tablets market. The concentration of medicines taken orally is significantly reduced medication before it enters the bloodstream, and here is where the ability of Orally Disintegrating Tablets to prevent first-pass metabolism helps solve such problems. Orally disintegrating tablets with higher bioavailability for protein and peptide-based therapies are a feasible option for delivering high molecular weight medicines, and this aspect is expected to drive the Orally Disintegrating Tablet Market growth in the coming years.

The North America Orodispersible Tablets Market Holds A Significant Revenue Share

The North American market for orodispersible tablets is expected to hold the largest market share in revenue shortly. The region is experiencing growth primarily because of the established presence of pharmaceutical companies, a strong healthcare infrastructure, and substantial healthcare spending. An increasing prevalence of chronic diseases, a growing elderly population, and a heightened focus on patient-centered treatments also drive the region. Technological advancements, robust regulatory frameworks, and high awareness among healthcare professionals and patients fuel the region's market growth.

However, the Asia Pacific region is projected to exhibit rapid growth in the global market for orodispersible tablets. This growth is driven by the region's large population, escalating healthcare costs, and increasing awareness of innovative medication delivery technologies. Rapidly emerging economies like China and India are witnessing a rise in chronic diseases and a demand for user-friendly drug administration methods, creating opportunities for the orodispersible tablets market.

Orodispersible Tablets Market Report Scope: